Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Colorectal cancer (CRC) is the third most common cancer globally and presents a significant challenge owing to its high mortality rate and the limitations of traditional treatment options such as surgery, radiotherapy, and chemotherapy. While these treatments are foundational, they are often poorly...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1350208
Main Authors Shebbo, Salima, Binothman, Najat, Darwaish, Manar, Niaz, Hanan A., Abdulal, Rwaa H., Borjac, Jamilah, Hashem, Anwar M., Mahmoud, Ahmad Bakur
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 12.03.2024
Subjects
Cancer Vaccines
CAR-T therapy
colorectal cancer
Colorectal Neoplasms
combinational therapy
Humans
immune-checkpoints inhibitors
Immunology
Immunotherapy - methods
Immunotherapy, Adoptive
Treatment Outcome
vaccines
combinational therapy
immune-checkpoints inhibitors
colorectal cancer
vaccines
CAR-T therapy
Online AccessGet full text

Cover

More Information
Summary:Colorectal cancer (CRC) is the third most common cancer globally and presents a significant challenge owing to its high mortality rate and the limitations of traditional treatment options such as surgery, radiotherapy, and chemotherapy. While these treatments are foundational, they are often poorly effective owing to tumor resistance. Immunotherapy is a groundbreaking alternative that has recently emerged and offers new hope for success by exploiting the body’s own immune system. This article aims to provide an extensive review of clinical trials evaluating the efficacy of various immunotherapies, including CRC vaccines, chimeric antigen receptor T-cell therapies, and immune checkpoint inhibitors. We also discuss combining CRC vaccines with monoclonal antibodies, delve into preclinical studies of novel cancer vaccines, and assess the impact of these treatment methods on patient outcomes. This review seeks to provide a deeper understanding of the current state of CRC treatment by evaluating innovative treatments and their potential to redefine the prognosis of patients with CRC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Ganjun Yu, Second Military Medical University, China
Edited by: Zong Sheng Guo, University at Buffalo, United States
Thanh Huong Phung, Hanoi University of Pharmacy, Vietnam
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1350208